

February 27, 2026

Notice Regarding Offer of Refunds to 340B Covered Entities from Civica, Inc.

Civica, Inc. has recently recalculated 340B ceiling prices for the NDC’s referenced below for the time period of September 1, 2024 through November 30, 2025. Civica has determined that a refund is or may be owed to 340B Covered Entities that purchased any of the below NDC’s during the time period of September 1, 2024 through November 30, 2025.

The recalculated Ceiling Prices are the result of revised pricing data.

Time Period	NDC	Product Description
Sept. 1, 2024 through Nov. 30, 2025	72572-801-02	Vancomycin Hydrochloride for Injection, USP 1 gram per vial
Sept. 1, 2024 through Nov. 30, 2025	72572-805-01	Vancomycin Hydrochloride for Injection, USP 10 grams per Pharmacy Bulk Package vial
Sept. 1, 2024 through Nov. 30, 2025	72572-100-01	DAPTOmycin for Injection 350 mg/vial
Sept. 1, 2024 through Nov. 30, 2025	72572-102-01	DAPTOmycin for Injection 500 mg/vial

Civica uses wholesaler chargeback records to calculate refunds owed to impacted eligible Covered Entities, and intends to refund those amounts in the form of a credit from the wholesaler. Separate memos will be sent regarding the credit and the applicable NDCs.

Civica Inc. has asked the Health Resources and Services Administration (HRSA) to post this Notice on the HRSA public website to ensure transparency for all 340B Covered Entities regarding Civica’s Ceiling Price recalculations. Covered Entities that believe they may be entitled to a refund but does not receive credit, or who have any questions and/or requests for additional information, may contact Civica Inc. at the following email address:

governmentprograms@civicarx.org.